Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCE and G-CSF for PBSC Mobilization in CML
NCT00002674Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Oct 1994
- Primary completion
- Mar 2000
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mitoxantrone, cytarabine, etoposide and filgrastim in chronic myeloid leukemia (CML), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Efficacy of MCE followed by G-CSF to mobilize peripheral blood stem cells and Toxicity of the MCE and G-CSF regimen. Started Oct 1994; status: completed.
02
Drugs
mitoxantronecytarabineetoposidefilgrastim
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00002674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002674.